As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to EMA in 2017 about Draft guideline: Notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol can be found below.